US 12,084,506 B2
Methods of treating a canine and inhibiting NGF activity through use of anti-NGF antibodies
Sebastian C. J. Steiniger, Kalamazoo, MI (US); William Dunkle, Kalamazoo, MI (US); Catherine Rugg, Cronulla (AU); and Steven A. Dunham, Kalamazoo, MI (US)
Assigned to Zoetis Services LLC, Parsippany, NJ (US)
Filed by Zoetis Services LLC, Parsippany, NJ (US)
Filed on Mar. 3, 2021, as Appl. No. 17/190,618.
Application 17/190,618 is a division of application No. 16/251,293, filed on Jan. 18, 2019, granted, now 10,982,002.
Claims priority of provisional application 62/641,538, filed on Mar. 12, 2018.
Prior Publication US 2021/0214449 A1, Jul. 15, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/18 (2006.01); A61K 31/713 (2006.01); A61K 39/395 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); A61P 9/10 (2006.01); A61P 29/02 (2006.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01); C12N 15/11 (2006.01); C12N 15/63 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2875 (2013.01) [A61K 31/713 (2013.01); A61K 39/39533 (2013.01); A61P 3/04 (2018.01); A61P 3/10 (2018.01); A61P 9/10 (2018.01); A61P 29/02 (2018.01); C07K 16/22 (2013.01); C12N 15/11 (2013.01); C12N 15/63 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/30 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 2 Claims
 
1. A method of treating a canine for pain comprising administering to said canine a therapeutically effective amount of a veterinary composition comprising an anti-Nerve Growth Factor (NGF) antibody comprising a variable light chain comprising the amino acid sequence of SEQ ID NO: 7 and a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 8.